Cyclic Dinucleotide Compounds for Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies face challenges such as the emergence of drug-resistant variants, long-term treatment requirements, unwanted side effects, and genotype-specific drug ineffectiveness, necessitating a new approach that activates the host immune response and is agnostic to viral genotypes.
Innovation Solution
Development of cyclic dinucleotide compounds that induce the expression of pattern recognition receptors (PRRs) like STING and RIG-I, activating the innate immune system to combat microbial infections and cancer, by administering specific cyclic dinucleotide compounds or their compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral therapies are used, then viral infection is treated, but drug-resistant variants emerge and treatment requires persistent long-term therapy with unwanted side effects
Solution Approach 1:
The patent uses cyclic dinucleotide compounds as intermediaries that activate the host's innate immune system (STING and RIG-I pathways) to fight viral infections. Instead of directly targeting the virus with antivirals, these compounds mediate immune system activation, producing type I interferons and other immune responses that eliminate viral infections while reducing direct drug-virus interaction that leads to resistance
Solution Approach 2:
The therapy enables the host immune system to serve itself by activating endogenous defense mechanisms through PRR induction. The immune system becomes self-sufficient in combating the infection, reducing reliance on persistent external drug administration and minimizing long-term side effects associated with prolonged antiviral therapy
2Reliability
If genotype-specific antiviral drugs are developed, then treatment is effective against specific viral genotypes, but the drugs are not active against other genotypes
Solution Approach 1:
The cyclic dinucleotide compounds activate universal host immune pathways (STING and RIG-I) that recognize and respond to diverse viral genotypes through conserved pattern recognition mechanisms. This universal immune activation provides broad-spectrum activity against multiple viral families and genotypes, eliminating the need for genotype-specific drug development
3Reliability
If pattern recognition receptors are activated to induce immune response, then antiviral activity and immune response activation are achieved, but the mechanism requires understanding of complex immune pathways
Solution Approach 1:
The cyclic dinucleotide compounds serve as simplified intermediaries that directly activate conserved PRRs (STING and RIG-I) without requiring complex dosing regimens or combination therapies. While the underlying immune pathways are complex, the therapeutic intervention itself is a single small molecule that reliably triggers the desired immune response through well-defined molecular targets
Data Source
AI summary
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.